Posted by Defense World Staff on Nov 27th, 2024
Prime Medicine (NYSE:PRME – Get Free Report) and Century Therapeutics (NASDAQ:IPSC – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.
Risk and Volatility
Prime Medicine has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500.
Insider & Institutional Ownership
70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 23.5% of Prime Medicine shares are held by company insiders. Comparatively, 6.8% of Century Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Prime Medicine and Century Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Prime Medicine | N/A | -107.87% | -74.97% |
| Century Therapeutics | -4,837.73% | -61.66% | -31.78% |
Analyst Ratings
This is a summary of current ratings and recommmendations for Prime Medicine and Century Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Prime Medicine | 0 | 1 | 8 | 0 | 2.89 |
| Century Therapeutics | 0 | 0 | 5 | 0 | 3.00 |
Prime Medicine presently has a consensus price target of $13.25, indicating a potential upside of 296.71%. Century Therapeutics has a consensus price target of $11.60, indicating a potential upside of 759.26%. Given Century Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Century Therapeutics is more favorable than Prime Medicine.
Valuation & Earnings
This table compares Prime Medicine and Century Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Prime Medicine | $800,000.00 | 547.60 | -$198.13 million | ($2.05) | -1.63 |
| Century Therapeutics | $2.23 million | 51.48 | -$136.67 million | ($1.85) | -0.73 |
Century Therapeutics has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Century Therapeutics beats Prime Medicine on 8 of the 14 factors compared between the two stocks.
About Prime Medicine
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.
About Century Therapeutics
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
You might be interested in:
B. Riley Boosts Ooma Price Target to $15.50
NIO Stock Rating Lowered by The Goldman Sachs Group
HC Wainwright Forecasts Mainz Biomed Q1 Earnings
Brokers Offer Predictions for MATW Q1 Earnings
What is William Blair’s Forecast for Mastercard Q1 Earnings?
